Search

Displaying results 7841 - 7850 of 8171 in total
  1. Drug

    HM-30181

    go.drugbank.com/drugs/DB14070
    Investigational

    Categories: P-glycoprotein inhibitors
  2. Drug

    Desmethylsertraline

    go.drugbank.com/drugs/DB14071
    Experimental

    Desmethylsertraline is a metabolite of sertraline.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Polysorbate 60

    go.drugbank.com/drugs/DB14153
    Investigational

    Categories: P-glycoprotein inhibitors
  4. Drug

    Phosphorus P-32

    go.drugbank.com/drugs/DB14551
    Investigational

    Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity.

    Synonyms: P-32, Phosphorus P-32
  5. Drug

    Hydroxyprogesterone

    go.drugbank.com/drugs/DB14570
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Fluprednidene acetate

    go.drugbank.com/drugs/DB14634
    Investigational

    Fluprednidene acetate is a corticosteroid. It has anti-inflammatory and anti-allergic properties.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  7. Drug

    Cannabinol

    go.drugbank.com/drugs/DB14737
    Investigational

    Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.

    Synonyms: 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-olCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inhibitors
  8. Drug

    Narlaprevir

    go.drugbank.com/drugs/DB14760
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    AZD-1656

    go.drugbank.com/drugs/DB14810
    Investigational

    AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).

  10. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates